文献速递皮肤肿瘤

黑色素瘤患者的胚系癌症易感基因分析

Germline cancer susceptibility in individuals with melanoma.
PubMed 文献 · J Am Acad Dermatol · 2024-03-20

验证队列的P/LP变异率为10.6%~15.8%。

要点

  • 黑色素瘤患者中胚系P/LP变异率可达15.3%。
  • 多数变异涉及非黑色素瘤相关基因,如BLM、CHEK2、MLH1等。
  • 近半变异位于同源重组修复缺陷基因,具有临床可干预性。

核心结论

  • 黑色素瘤患者中胚系易感性常见,临床可干预的发现率为10.6%至15.8%。

主要发现

  • 15.3%(61例)患者检出胚系致病/可能致病性变异。
  • 41例(67%)变异涉及非黑色素瘤相关基因(BLM、BRIP1、CHEK2、MLH1、MSH2、PMS2、RAD51C)。
  • 20例(33%)变异位于既往与家族性黑色素瘤相关的基因(BAP1、BRCA2、CDKN2A、MITF、TP53)。
  • 30例(46.9%)P/LP变异位于同源重组修复缺陷基因。

关键数值与推荐

  • 验证队列P/LP率:未选择肿瘤队列10.6%,选择商业检测队列15.8%,高度选择皮肤科研究14.5%。

临床怎么用

  • 对具有个人或家族癌症史的黑色素瘤患者应考虑胚系基因检测,以识别可干预的遗传变异。

局限性

  • 队列选择程度不一,部分为回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prior studies have estimated a small number of individuals with melanoma (2%-2.5%) have germline cancer predisposition, yet a recent twin study suggested melanoma has the highest hereditability among cancers. OBJECTIVE: To determine the incidence of hereditary melanoma and characterize the spectrum of cancer predisposition genes that may increase the risk of melanoma. METHODS: Four hundred individuals with melanoma and personal or family history of cancers underwent germline testing of >80 cancer predisposition genes. Comparative analysis of germline data was performed on 3 additional oncologic and dermatologic data sets. RESULTS: Germline pathogenic/likely pathogenic (P/LP) variants were identified in 15.3% (61) individuals with melanoma. Most variants (41, 67%) involved genes considered unrelated to melanoma (BLM, BRIP1, CHEK2, MLH1, MSH2, PMS2, RAD51C). A third (20, 33%) were in genes previously associated with familial melanoma (BAP1, BRCA2, CDKN2A, MITF, TP53). Nearly half (30, 46.9%) of P/LP variants were in homologous repair deficiency genes. Validation cohorts demonstrated P/LP rates of 10.6% from an unselected oncologic cohort, 15.8% from a selected commercial testing cohort, and 14.5% from a highly selected dermatologic study. LIMITATIONS: Cohorts with varying degrees of selection, some retrospective. CONCLUSION: Germline predisposition in individuals with melanoma is common, with clinically actionable findings diagnosed in 10.6% to 15.8%.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Funchain P, Ni Y, Heald B, et al. Germline cancer susceptibility in individuals with melanoma. J Am Acad Dermatol. 2024. PMID: 38513832. doi:10.1016/j.jaad.2023.11.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。